Low-burden p53 mutations were proved to exert a detrimental prognostic effect in CLL patients who did not receive treatment, since p53 mutations existed before the therapy of CLL patients and grew to become the predominant clone during patients’ relapse [137]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.